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Abstract
Background
Patients with chronic kidney disease (CKD) are at increased risk for heart failure (HF). We
aimed to investigate differences in proteins associated with HF hospitalizations among
patients with and without CKD in the Heart and Soul Study.
Methods and results
We measured 1068 unique plasma proteins from baseline samples of 974 participants in
The Heart and Soul Study who were followed for HF hospitalization over a median of 7
years. We sequentially applied forest regression and Cox survival analyses to select prog-
nostic proteins. Among participants with CKD, four proteins were associated with HF at Bon-
ferroni-level significance (p<2.5x10-4): Angiopoietin-2 (HR[95%CI] 1.45[1.33, 1.59]),
Spondin-1 (HR[95%CI] 1.13 [1.06, 1.20]), tartrate-resistant acid phosphatase type 5 (HR
[95%CI] 0.65[0.53, 0.78]) and neurogenis locus notch homolog protein 1 (NOTCH1) (HR
[95%CI] 0.67[0.55, 0.80]). These associations persisted at p<0.01 after adjustment for age,
estimated glomerular filtration and history of HF. CKD was a significant interaction term in
the associations of NOTCH1 and Spondin-1 with HF. Pathway analysis showed a trend for
higher representation of the Cardiac Hypertrophy and Complement/Coagulation pathways
among proteins prognostic of HF in the CKD sub-group.
Conclusions
These results suggest that markers of heart failure differ between patients with and without
CKD. Further research is needed to validate novel markers in cohorts of patients with CKD
and adjudicated HF events.
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Introduction
The epidemic of chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR)
<60 ml/min/m2 or albuminuria>30mg/g) affects 20 million Americans.[1] Epidemiological
studies of both community-based[2–4] and high-risk populations[5–8] have confirmed that
CKD confers at least a two-fold increase in cardiovascular (CV) risk.[9] Patients with mild to
moderate CKD (eGFR 30–60 ml/min/m2) are at higher risk for dying of CV disease than pro-
gressing to end-stage renal disease.[7, 10] Albuminuria, itself sufficient to diagnose CKD
(according to Kidney Disease Improving Global Outcomes Consortium (KDIGO))[11] is an
independent risk factor for heart failure (HF) and myocardial infarction.[2, 12, 13]
HF is the most common CV event in the Chronic Renal Insufficiency Cohort (CRIC),[14,
15] in which the annual rates of HF, myocardial infarction and CV mortality are 1.5%, 0.8%
and 1.2%, respectively. Even in patients without CKD, small decrements in renal function
(measured by cystatin C), are associated with higher risk of incident HF.[4] Dysfunctional
pathways contributing to this high risk of HF putatively include sympathetic over-activity lead-
ing to renin-angiotensin activation[16], and in turn, volume overload;[17] inflammation and
volume overload leading to cardiac remodeling;[18] and inflammation,[19] oxidative stress
and higher levels of asymmetric dimethylarginine[20] leading to endothelial dysfunction.[21]
Unfortunately, we have few therapeutic targets within these pathways.
We sought to examine circulating proteins associated with HF among patients with CKD
and to discern differences in biological pathways leading to HF between patients with and
without CKD in the Heart and Soul Study.
Materials and methods
All participants provided written informed consent to participate in the Heart and Soul Study.
In these analyses, we included 974 participants with assessment of proteomics at baseline. Vet-
erans Affairs Institutional Review Boards at each site approved the study protocol. All records
were anonymized before statistical analysis.
Protein selection
Proteomics was measured in baseline samples by SomaLogic (Boulder, CO) using the SOMAs-
can aptamer-based proteomic assay as previously described.[22] Aptamers are short single
stranded RNA or DNA oligomers, synthesized as a core of 20–80 randomly selected nucleotide
bases flanked by constant base sequences that may be enzymatically modified.[23] Each apta-
mer has a unique three-dimensional shape and binds to a surface epitope of a non-denatured
protein.[24] Specificity of aptamer-protein pairs has been examined with methods including
high performance liquid chromatography, mass spectrometry, and western blot.[25] The final
list of 1068 proteins that we utilized in the current analyses was based on the SOMAscan ver-
sion used in the previous Heart and Soul analysis,[22] with the following exceptions. We did
not use quality control criteria to exclude any proteins; we did choose to include only proteins
labeled as ‘human’ in the dataset supplied by Heart and Soul investigators. (See S1 Table for a
list of proteins excluded from the analysis).
Short statistical methods
First, we examined baseline characteristics of the demographics and comorbidities among the
whole cohort, and groups with or without CKD. Categorical variables were evaluated by chi2.
For continuous variables, normality was evaluated by visual inspection, equal variance by F-
tests, and then Student’s t-tests, Welch’s t-tests, and Mann-Whitney tests were used as
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appropriate to evaluate differences in characteristics by CKD-status. We selected 1068 apta-
mers that were designated “human” and evaluated these as potential predictors in the random
survival forests. After normal standardization of the 1068 proteins, random survival forests
[26] were used to model time to HF hospitalization. Random forest regression models have
several advantages, including better integration of correlated variables, excellent predictive
qualities[27, 28] and the capacity to incorporate interactions between variables and non-linear
relationships in the model.[29] The candidate proteins selected in the CKD-subgroup were
further reduced by fitting a Cox Least Absolute Shrinkage and Selection Operator (LASSO)
regression model predicting heart failure in those with CKD. After eliminating less predictive
proteins by the Cox LASSO method, we fit separate Cox proportional hazards regression mod-
els for each of the final LASSO selected proteins predicting time to HF hospitalization in the
CKD subgroup, successively adjusting for baseline measures of age (continuous, years), eGFR
(continuous, ml/min/1.73m2) and history of heart failure (yes / no). To verify our LASSO anal-
ysis, we performed a sensitivity analysis. We repeated the Cox LASSO regression analyses in
the CKD-subgroup instead using the set of proteins selected in the random forest for the full
sample as potential predictors of heart failure hospitalization. Pearson’s correlation coefficients
were estimated between proteins selected in the CKD subgroup and eGFR or albuminuria in
the full sample of participants. Additionally, we tested interactions between the top predictive
proteins selected in random survival forest model for the full sample and CKD (yes / no), with
significance threshold for the interaction term at p<0.05. Data management and statistical
analyses were conducted using R version 3.3.0.[30] Pathway analyses were performed using
Gene Ontology (geneontology.org) and WikiPathways (wikipathways.org). An organizational
chart for these analyses is shown in Fig 1 (below). A full description of the Heart and Soul
Study, statistical methods and pathway analyses is found in S1 File, Expanded Methods.
Results
Baseline characteristics
Among all 974 participants for whom proteomic data were available, mean age was 67 years,
18% were women, 17% had a history of HF and 54% had a history of myocardial infarction.
Fig 1. Analytic plan (See attached file). This flowchart depicts our analytic plan. Results of analyses in boxes shaded
grey were performed but had lower relevance to the project Aims and thus are not included in the manuscript. H&S:
Heart and Soul. LASSO: Least Absolute Shrinkage and Selection Operator. PH: proportional hazard.
https://doi.org/10.1371/journal.pone.0208042.g001
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The majority of participants (>80%) had ejection fraction >50% and either normal or mildly
impaired diastolic dysfunction. Over 1/3 of the participants had CKD (defined as eGFR<60 or
albuminuria>30mg/g); these participants were older and more likely to have a history of
hypertension, diabetes, MI or HF, or abnormal diastolic function (Table 1).
Results of random forest regression analyses
Among 974 participants included in these analyses, there were 192 heart failure hospitaliza-
tions over a mean(SD) follow-up of 7.0(3.2) years. Participants with CKD (N = 364) had a
higher age-adjusted rate of heart failure hospitalization than those without CKD (N = 572)
(66.17 cases per 1,000 person-years vs. 12.86 cases per 1,000 person-years, respectively). Ran-
dom survival forest analysis of the full sample, CKD participant sub-group, and non-CKD par-
ticipant sub-group yielded 331, 204 and 319 proteins associated with HF, respectively. As
shown in Fig 2 (below), prognostic proteins resulting from these three separate forest regres-
sions only partially overlapped. There were 43 proteins that emerged as prognostic factors
among the CKD subgroup of participants, but were not selected by forest regression of the full
sample or the non-CKD sub-group. These 43 proteins and the full list of 204 proteins resulting
from forest regression in the CKD sub-group are listed in S2 Table. As a sensitivity analysis,
we performed Cox LASSO on the set of proteins selected in the random forest for the full sam-
ple as potential predictors of heart failure hospitalization. We found the same ten proteins in
the Cox LASSO models when applied to the full cohort or the CKD-subgroup—in the full
cohort, we also found one additional protein. The consistent findings between the whole
group and CKD subgroup support that variable selection and fine tuning of lambda value were
correctly performed.
Interaction with CKD
For each of the 331 proteins generated from the random forest regression of the full sample of
974 participants, we calculated the Cox survival hazard ratio, adjusted for age and eGFR, and
then tested these associations for an interaction with CKD. CKD had a significant interaction
with 43 proteins at a significance of p<0.05. There were two CKD interactions with Bonfer-
roni-corrected statistical significance: Spondin-1 (CKD HR, [95%CI] 1.11[1.04, 1.19], non-
CKD HR, [95%CI] 2.16 [1.63, 2.86], p-value for interaction 1.4 x10-6; and Inhibin beta A chain
(CKD HR, [95%CI] 0.82 [0.68, 0.99], non-CKD HR, [95%CI] 1.40 [1.17, 1.68]], p-value for
interaction 8.6 x10-5. NOTCH1 was significantly associated with lower risk of heart failure in
the CKD sub-group, but it was not significantly associated with HF outcomes in the non-CKD
sub-group (CKD HR, [95%CI] 0.67 [0.56, 0.81], non CKD HR, [95%CI] 1.07 [0.82, 1.39], p-
value for interaction 0.007. CD109 antigen showed a similar pattern of lower risk among par-
ticipants with CKD, although CD109 was not selected by forest regression, and its hazard ratio
among CKD participants was not significant. Vascular endothelial growth factor receptor 3,
although it was not selected by random forest regression, was associated with higher risk of
heart failure among patients with CKD (HR 1.4 [95%CI 1.16, 1.69]), and further, this was sig-
nificantly higher risk than among patients without CKD (HR 1.04 [0.79, 1.37]) (p-value for
CKD interaction 0.049). (S3 Table) Among patients in the CKD sub-group, we also performed
an interaction analysis with DM for each of the 10 proteins selected by LASSO, and found no
significant interactions (p>0.1 for all 10 proteins).
Cox LASSO regression and multivariable analysis
Using the set of 204 proteins generated from random forest analyses of the CKD sub-group,
we performed Cox LASSO regression to select proteins with the strongest associations with
Proteomics of heart failure in Heart and Soul
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Table 1. Baseline patient characteristics in total sample and in sub-groups stratified on chronic kidney disease.
Total CKD No CKD p-value�
n 974 364 572
Demographic factors
Age (years) 66.8 (11.0) 70.8 (11.1) 64.3 (10.2) <0.001
Male sex 797 (82%) 300 (82%) 469 (82%) 0.94
White race 587 (60%) 223 (61%) 345 (60%) 0.83
Clinical history
Hypertension 689 (71%) 281 (77%) 382 (67%) <0.001
Revascularization 571 (59%) 231 (64%) 325 (57%) 0.04
Diabetes 253 (26%) 132 (36%) 112 (20%) <0.001
History of myocardial infarction 523 (54%) 218 (60%) 284 (50%) 0.003
History of heart failure 169 (17%) 91 (25%) 69 (12%) <0.001
Stroke 136 (14%) 61 (17%) 70 (12%) 0.08
Body mass index 28.4 (5.4) 28.5 (5.9) 28.5 (5.1) 0.98
Current smoking 190 (20%) 61 (17%) 119 (21%) 0.14
Regular alcohol use 284 (29%) 87 (24%) 180 (32%) 0.02
Resting Systolic blood pressure (mmHg) 132.9 (21.1) 136.4 (22.5) 130.8 (20.2) <0.001
Resting Diastolic blood pressure (mmHg) 74.6 (11.4) 74.3 (12.1) 74.9 (11.0) 0.44
NYHA Class III or IV 217 (22%) 99 (27%) 108 (19%) 0.003
Medication use
Aspirin 705 (72%) 255 (70%) 421 (74%) 0.17
Statin 627 (64%) 230 (63%) 370 (65%) 0.54
ACE-inhibitor / ARB 499 (51%) 220 (60%) 262 (46%) <0.001
Beta-blockers 565 (58%) 238 (65%) 307 (54%) <0.001
Diuretics 288(30%) 152(42%) 125(22%) <0.001
Laboratory data
Cholesterol, mean(SD) (mg/dl)
Total 177.5 (42.5) 176.1 (43.5) 178.3 (42.0) 0.44
HDL 45.6 (14.1) 44.4 (13.8) 46.2 (14.2) 0.06
LDL 104.3 (34.0) 103.3 (35.9) 105.1 (32.9) 0.44
Triglycerides 140.0 (125.1) 146.3 (119.5) 137.1 (129.4) 0.27
GFR, mean(SD) (ml/min/1.73m2) 70.6 (22.1) 51.9 (20.2) 81.7 (14.1) <0.001
Albuminuria, mean(SD) (mg/g) 63.6 (278.0) 157.1 (440.8) 8.3 (5.6) <0.001
Hemoglobin, mean(SD) (g/dL) 13.9 (1.4) 13.4 (1.5) 14.1 (1.3) <0.001
Cardiac function
LVEF (%) 61.7 (9.7) 59.9 (10.3) 62.7 (9.3) <0.001
Diastolic function
Normal 530 (54%) 153 (42%) 353 (62%) <0.001
Impaired relaxation 227 (23%) 109 (30%) 109 (19%)
Pseudonormal 60 (6%) 33 (9%) 27 (5%)
Restrictive 45 (5%) 24 (7%) 18 (3%)
�P-values for differences between CKD and non-CKD participants were determined by chi-squared for categorical variables, and Student’s t-test (age, lipid tests), T-test
using Welch’s correction for unequal variances (BMI, systolic and diastolic blood pressure, eGFR, hemoglobin, LVEF) or Mann-Whitney tests (albuminuria) for
continuous variables. Continuous data are summarized as mean (SD) or number participants (percent cohort). NYHA: New York Heart Association. ACE: angiotensin
converting enzyme ARB: angiotensin receptor blocker. HDL high density lipoprotein. LDL low density lipoprotein. GFR glomerular filtration rate. LVEF Left
ventricular ejection fraction
https://doi.org/10.1371/journal.pone.0208042.t001
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HF hospitalizations. Ten proteins remained in the final Cox LASSO model; eight were associ-
ated with higher risk of HF, and two were associated with lower risk of HF. Cox proportional
hazards analyses (without LASSO) were then conducted separately for each of these 10 pro-
teins. In unadjusted Cox models, four proteins qualified as statistically significant by a Bonfer-
roni-corrected p-value < 0.05/204 (2.5x10-4). Angiopoietin-2 (ANGPT2) was associated with
higher risk of HF(HR[95%CI] 1.45[1.33, 1.59]), as was Spondin-1 (HR[95%CI] 1.45[1.33,
1.59]), while tartrate-resistant acid phosphatase type 5 (TRAP5) (HR[95%CI] 0.65[0.53, 0.78])
and neurogenis locus notch homolog protein 1 (NOTCH1) (HR[95%CI] 0.67[0.55, 0.80])
were associated with lower risk. ANGPT2 and TRAP5 associations retained Bonferroni-level
significance after adjustment for age, eGFR and baseline HF. The prognostic associations of
NOTCH1 and Spondin-1 were attenuated after adjustment for history of heart failure, but
remained significant at p<0.01. (Table 2) Further adjustment for diabetes and hypertension
did not substantially attenuate hazard ratios for ANGPT2, Spondin-1, TRAP5 or NOTCH1.
Correlations of markers with eGFR and albuminuria
We examined whether the ten proteins selected after Cox LASSO regression in the CKD sub-
group were correlated with renal function in the full sample (N = 974 participants). Five of the
proteins associated with higher risk correlated with worse renal function (either lower eGFR
or higher albuminuria): angiopoietin-2 (ANGPT2), C-C motif chemokine 18 (CCL18), C-C
motif chemokine 13 (CCL13), Spondin-1(SPON1) and hepatocyte growth factor. Conversely,
the two proteins associated with lower risk were associated with better renal function:
Fig 2. Results of random forest regression performed on full sample and sub-groups stratified by chronic kidney
disease (See Attached File). Random survival forest regression was applied first to the full sample (N = 974
participants), then to the sub-groups with baseline CKD (N = 364 participants) and without baseline CKD (N = 572
participants). Forest regression of the full sample of participants yielded 331 proteins associated with HF outcomes
(blue circle). Analysis of the sub-group with CKD resulted in 204 proteins (yellow circle), and analysis of the sub-group
without CKD yielded 319 proteins (orange circle).
https://doi.org/10.1371/journal.pone.0208042.g002
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Tartrate-resistant acid phosphatase type 5 (TRAP5) and Neurogenis locus notch homolog pro-
tein 1 (NOTCH1) (Table 3).
Pathway analyses
We performed functional enrichment on subsets of proteins derived from forest analysis of
proteins in three participant samples: a) the full sample, b) participants with CKD and c) par-
ticipants without CKD. In both of these participant sub-groups we performed functional
enrichment of the proteins associated with HF using two systems: Gene Ontology (geneontol-
ogy.org) and Wikipathways (wikipathways.org). All 1068 proteins were identified in each of
Table 2. Hazard ratios and 95% confidence interval per 1-SD predicting time to heart failure hospitalization among those with chronic kidney disease� (N = 364),
heart and soul study.
Model 1 p-value Model 2 p-value Model 3 p-value Model 4 p-value
Higher heart failure risk
Angiopoietin-2 1.45 (1.33, 1.59) 3.33E-16 1.48 (1.35, 1.63) 0.0238 1.45 (1.31, 1.60) 0.0446 1.41 (1.28, 1.55) 7.08E-12
C-C motif chemokine 18 1.25 (1.11, 1.42) 0.000411 1.25 (1.10, 1.42) 0.00057 1.21 (1.05, 1.38) 0.00654 1.19 (1.04, 1.37) 0.01287
C-X-C motif chemokine 13 1.17 (1.07, 1.28) 0.000513 1.17 (1.07, 1.29) 0.00051 1.21 (1.10, 1.33) 0.000146 1.18 (1.07, 1.29) 0.000669
Spondin-1 1.13 (1.06, 1.20) 0.000201 1.11 (1.04, 1.19) 0.00137 1.11 (1.04, 1.19) 0.00295 1.11 (1.04, 1.19) 0.002096
TATA-box-binding protein 1.11 (1.02, 1.20) 0.0126 1.10 (1.01, 1.19) 0.0249 1.10 (1.02, 1.19) 0.017 1.11 (1.02, 1.20) 0.011858
Kallikrein-7 1.11 (1.03, 1.18) 0.00331 1.11 (1.04, 1.19) 0.00219 1.10 (1.02, 1.17) 0.00851 1.08 (1.01, 1.15) 0.027749
Hepatocyte growth factor 1.09 (1.02, 1.17) 0.0121 1.10 (1.03, 1.18) 0.00561 1.11 (1.04, 1.19) 0.00287 1.13 (1.05, 1.21) 0.000865
Carbohydrate sulfotransferase 2 1.05 (0.99, 1.11) 0.119 1.05 (0.99, 1.12) 0.1097 1.09 (1.02, 1.16) 0.014728 1.07 (1.00, 1.14) 0.03713
Lower heart failure risk
Tartrate-resistant acid phosphatase type 5 0.65 (0.53, 0.78) 7.00E-06 0.65 (0.54, 0.79) 1.58E-05 0.66 (0.55, 0.80) 1.91E-05 0.68 (0.56, 0.82) 4.30E-05
Neurogenis locus notch homolog protein 1 0.67 (0.55, 0.80) 1.69E-05 0.66 (0.55, 0.79) 9.23E-06 0.67 (0.56, 0.81) 4.01E-05 0.72 (0.60, 0.88) 0.00106
Model 1—crude model; Model 2—adjusted for age (years); Model 3—adjusted for age (years) and eGFR; Model 4—adjusted for age, eGFR, and history of heart failure.
�Chronic kidney disease defined as eGFR<60 or albuminuria > 30 mg/g.
https://doi.org/10.1371/journal.pone.0208042.t002
Table 3. Pearson’s correlation coefficients between proteins predicting heart failure and egfr, or albuminuria in full sample�.
Molecular
Weight (kDa)
eGFR (ml/min/1.73m2) Albuminuria
(mg/g Cr)
Higher heart failure risk
Angiopoietin-2 57 -0.28 (<0.001) 0.12 (<0.001)
C-C motif chemokine 18 7.8 -0.36 (<0.001) 0.09 (0.006)
C-X-C motif chemokine 13 13 -0.10 (0.001) 0.02 (0.47)
Spondin-1 27 -0.21 (<0.001) 0.07 (0.049)
TATA-box-binding protein 38 -0.02 (0.51) -0.01 (0.75)
Kallikrein-7 86 -0.06 (0.06) -0.004 (0.89)
Hepatocyte growth factor 103 -0.01 (0.81) 0.08 (0.01)
Carbohydrate sulfotransferase 2 53 0.04 (0.22) -0.01 (0.79)
Lower heart failure risk
Tartrate-resistant acid phosphatase type 5 35 0.17 (<0.001) 0.05 (0.14)
Neurogenis locus notch homolog protein 1 120 0.24 (<0.001) -0.08 (0.02)
�Proteins were selected in survival random forests and Cox LASSO regression models predicting heart failure hospitalization in those with CKD. Pearson’s correlation
coefficients were estimated between these proteins and eGFR or Albuminuria in the full study sample. LASSO: Least absolute shrinkage and selection operator. eGFR:
estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0208042.t003
Proteomics of heart failure in Heart and Soul
PLOS ONE | https://doi.org/10.1371/journal.pone.0208042 December 17, 2018 7 / 15
these two systems. Overall, proportional representation of pathways in the subset of 331 pro-
teins associated with HF in the full sample was similar to the background of 1068 proteins. The
most common Gene Ontology pathways in these two subsets, listed by pathway, (% of 331 pro-
teins/% of 1068 proteins) were as follows: extracellular space (39%/34%), inflammatory
response (10%/12%), regulation of response to wounding (11%/12%), cell surface (12%/11%),
and coagulation (12%/15%). We then performed functional enrichment of the set of 204 pro-
teins derived from random forest regression among persons in the CKD sub-group and com-
pared this with the background of 1068 proteins. Using pathways defined by Wikipathways,
the protein set derived from the CKD sub-group had a higher proportion of proteins in the
Cardiac Hypertrophy (chi2 p = 0.17) and Complement/Coagulation pathway (chi2 p = 0.13),
although these differences did not reach statistical significance. We mapped proteins associ-
ated with HF among CKD participants to the Complement/Coagulation pathway. These pro-
teins included Coagulation factor VII (F7), plasma kallikrein (KLKB1), alpha-1-antitrypsin
(SERPINA1), Vitamin K-dependent protein S (PROS1), urokinase plasminogen activator sur-
face receptor (PLAUR) and Complements 6–9. (Fig 3, below)
Discussion
In this study, we utilized the SOMAscan aptamer-based proteomic assay to perform an agnos-
tic search for novel proteins associated with HF hospitalizations in the Heart and Soul Study
and to characterize protein-HF pathways and risk associations according to CKD status. Our
analysis highlights 10 proteins associated with risk of HF in participants of Heart and Soul
with baseline CKD, four of which are associated with HF at Bonferroni-level significance
(p<2.5x10-4): ANGPT2, Spondin-1, TRAP5, and NOTCH1. These 4 proteins relate to angio-
genesis or atherogenesis, and their associations persist at p<0.01 after adjustment for age,
eGFR and history of HF. CKD is a significant interaction term in the NOTCH1-HF associa-
tion, and this association may be particularly important for patients with CKD.
Patients with CKD have high rates of HF,[31] but we lack a mechanistic explanation for this
phenomenon. Our goal was to identify novel proteins associated with the specific outcome of
HF hospitalizations, and to examine whether any of these associations differed among sub-
groups with and without CKD. Previously, Ganz et al. developed a proteomics risk score for
composite cardiovascular events (myocardial infarction, stroke, heart failure) and overall mor-
tality (CVD9) in Heart and Soul and validated the risk score in the HUNT3 cohort.[22] Our
analysis differs in its focus on HF hospitalizations, and our mechanistic interest in the role of
CKD in protein-HF associations. It is notable that, despite these different analytic approaches,
two proteins included in the 9 protein risk model developed by Ganz et al. were also selected
to our final list of 10 proteins associated with heart failure among the CKD sub-group: Angio-
poietin-2 and C-C motif chemokine 18. Three other proteins in the CVD9 model have roles in
the complement/coagulation pathway, which showed a trend for higher representation among
proteins selected in the CKD sub-group: complement 7, SERPINA3, SERPINF2. Thus, we feel
our results both corroborate and expand on the prior analysis.
The NOTCH1 protein was associated with lower risk of HF in the CKD sub-group after
multivariable adjustment for age, eGFR and HF. In the full sample, baseline CKD status had a
significant interaction with the NOTCH1-HF association, suggesting that this marker may
have particular importance for patients with CKD. The NOTCH1 pathway has central roles in
endothelial cell senescence and atherogenesis.[32, 33] In angiogenesis, NOTCH1 in endothe-
lial tip cells regulates angiogenic sprouting.[34, 35] Activation of NOTCH1 ameliorates cardiac
injury after MI.[36] It is important to note that NOTCH1 is a cell membrane receptor, and we
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have measured it in the extracellular space. Further studies are needed to delineate whether
serum levels correlate with NOTCH1 pathway activity.
Fig 3. Mapping Clinical Outcome Information to the Complement and Coagulation Pathway (See Attached File). The Coagulation and Complement pathway is
shown in this diagram, (source: https://www.wikipathways.org/index.php/Pathway:WP558.) Colored boxes represent results from random forest survival analyses. Gray
boxes represent proteins associated with heart failure when the full sample was analyzed. Green boxes represent proteins that were associated with HF after analysis of
the non-CKD sub-group. Yellow boxes represent proteins associated with HF after analysis of the CKD sub-group, including F7(Coagulation factor VII precursor),
SERPINA1(Alpha-1-antitrypsin precursor), PROS1(Vitamin K dependent protein S precursor), PLAUR(Urokinase plasminogen activator surface receptor), KLKB1
(Plasma kallikrein precursor), Complement(C)6, C7, C8-gamma chain, C9. Coagulation factors 3, 8, 12 and MASP2 were not measured.
https://doi.org/10.1371/journal.pone.0208042.g003
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We found TRAP5 to be associated with lower risk of HF hospitalization among participants
with CKD after adjustment for age, eGFR and baseline HF. TRAP5 is a metalloenzyme found
in osteoclasts and macrophages, known to be resistant to inhibition by tartrate and activated
in acidic conditions.[37] It is commonly used as a histological marker of osteoclasts, but also
has important functions in bone metabolism, immunity and cell growth and differentiation.
[38] Inactivating mutations of the TRAP5 gene deregulate osteopontin signaling,[39] an
important causal pathway of atherogenesis.[40, 41] It is interesting to note that CD109, a pro-
tein found in osteoclast precursors,[42] as well as activated platelets and T-cells,[43] was asso-
ciated with lower risk of heart failure among CKD participants than among non-CKD
participants, (p-value for CKD interaction = 0.049). CD109 did not appear in the list of pro-
teins associated with heart failure generated by random forest regression.
Spondin-1 (SPON1), also known as F-spondin, is a secreted protein of the thrombospondin
family, found primarily in the extracellular matrix. SPON1 deficient mice have upregulated
bone deposition and higher bone mass.[44] High concentrations of F-spondin are found in
the human ovary, where it is known to stimulate vascular smooth muscle cell proliferation.
[45] Given the negative Spearman correlation of Spondin-1 with eGFR and albuminuria, it fol-
lows that Spondin-1 levels were lower in those with higher eGFR, yet the Spondin-1-HF asso-
ciation was significantly stronger in these non-CKD patients. This could be due to a saturation
point of Spondin-1 or its effectors, and warrants further study.
ANGPT2 was associated with a higher risk of HF among patients with CKD, even after
adjustment for age, eGFR and baseline HF. ANGPT2 inhibits angiogenesis when VEGF is low
(as in CKD),[46, 47] but promotes angiogenesis when VEGF levels are high.[48] ANGPT2 is
produced and stored in endothelial cells and is released when exposed to TNF, VEGF, or hyp-
oxia.[49] Serum levels of ANGPT2 inversely correlate with eGFR and are elevated in patients
with advanced stages of CKD.[50] Circulating ANGPT2 is associated with mortality among
patients with heart failure with reduced ejection fraction[51] and is associated with early car-
diovascular disease in children with end-stage renal disease on dialysis.[52] ANGPT2 is
included in the proteomic risk score for composite cardiovascular events and death that was
developed in Heart and Soul by Ganz et al.[22] Although it was not selected by random forest
regression, vascular endothelial growth factor receptor 3 is another angiogenic factor associ-
ated with higher risk of heart failure among patients with CKD, and this association was mar-
ginally stronger in those with CKD than in those without CKD (p-value for CKD
interaction = 0.049). These findings support further work to explore the impact of angiogenic
factors on heart failure among patients with CKD.
Overall, among the 10 proteins selected in the CKD sub-group, serum levels of 6 proteins
correlated with eGFR. Of these 6, those associated with higher risk of HF correlated with lower
eGFR, and those associated with lower risk of HF correlated negatively with higher eGFR. One
challenge in researching biomarkers of cardiovascular disease in patients with CKD is that serum
levels of smaller molecules (typically<30kDa) are influenced directly by glomerular filtration,
and it can be difficult to determine whether a smaller molecule is simply a marker of CKD or if it
plays an active biological role in causing disease. Direct glomerular filtration could influence the
levels of three of the smaller proteins found to have negative correlations with eGFR (C-C motif
chemokine 18, C-X-C motif chemokine 13, and Spondin-1). The positive correlations of TRAP5
and NOTCH1 with eGFR would not be explained by this mechanism. We show that adjustment
for eGFR had minimal effect on HF associations of the 10 selected proteins. In particular, the asso-
ciations of TRAP5 and NOTCH1 with lower risk of HF remained significant at Bonferroni-level
p-value after adjustment for eGFR. These observations suggest that TRAP5 and NOTCH1 may
have active biological roles in the development or recurrence of HF. Further analyses of these
markers in CKD and non-CKD HF cohorts are needed to confirm these hypotheses.
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Functional enrichment illustrates the relative importance of biological pathways and ontol-
ogy terms, and in the case of pathways, illustrates the upstream or downstream position of a
particular protein in the pathway. By comparing functional enrichment of the 204 proteins
selected from random survival forest regression among patients with CKD to the background
set of 1068 proteins included in our analysis, we found that Cardiac Hypertrophy and Comple-
ment/Coagulation pathways were somewhat more prominent (although differences did not
reach statistical significance), relative to the background of 1068 proteins. These results are
consistent with what we know about cardiovascular disease in patients with CKD, in whom
left ventricular hypertrophy[53] and abnormal bleeding and coagulation[54, 55] are common.
However, it is important to consider that stable coronary artery disease was an inclusion crite-
ria for the Heart and Soul Study. In this specialized population, recurrent myocardial ischemia
related to atherosclerotic disease may be closely related to recurrent or incident heart failure
events, and this may account for our observation of a trend for higher representation of pro-
teins in the complement and coagulation pathway. It is also notable that the aptamer platform
used for this study did not measure all components of the complement / coagulation cascade;
further analysis of these pathways should be performed with aptamer platforms that cover a
larger range of proteins. We have provided a novel perspective on pathway analysis by incor-
porating clinical outcome information with the map of the coagulation pathway, to illustrate
an approach that may help us to understand differences in mechanisms of heart failure
between subgroups of patients with and without CKD.
There are several important limitations to the current analysis. Patients in the Heart and
Soul Study all had coronary artery disease, and thus our results may not generalize to HF of
non-ischemic origin. Further studies would be needed to understand if the proteins selected in
our analysis are markers of non-ischemic heart failure. Another important step in future
research will be to examine how proteomics differ between patients with heart failure pre-
served ejection fraction and heart failure reduced ejection fraction, which we did not differen-
tiate. Future studies might also clarify whether proteomic risk factors differ in patients on
different preventive treatments, such as statins. Etiology of CKD was not adjudicated in Heart
and Soul, and it is possible that mechanisms of cardiovascular disease differ among CKD
patients with different etiologies of kidney disease—e.g., hypertension, or glomerulonephritis.
Further studies in cohorts with a large, more diverse sample of CKD patients might elucidate
these differences. Conclusions from this study are limited prior to validation in larger cohorts.
Our analysis included 1068 proteins, a small portion of the human proteome; there are likely
to be other proteins essential to HF risk that were not measured. Functional enrichment per-
formed on these HF risk factors relative to the background of the SOMAscan assay may also
obscure pathways that might emerge if we could compare our subset of HF factors to a larger,
random sample of the proteome. Further, since our proteomic investigation was limited to
plasma, pathway analyses may not represent tissue-specific biological mechanisms. The core
proteomic dataset we utilized was the same as for the prior analysis by Ganz et al.,[22] but we
had slightly different criteria for excluding proteins from the analysis: we chose not to exclude
proteins based on quality metrics, but we did exclude 28 proteins (including troponin I) not
designated as ‘human’ targets in the Heart and Soul dataset. None of the 10 proteins selected
by forest and Cox LASSO regression in the CKD sub-group were noted to have poor quality
metrics in the prior analyses.
Conclusions
Despite these limitations, our analysis revealed four proteins associated with HF risk among
patients with CKD in Heart and Soul. In particular, NOTCH1, a regulator of angiogenesis, was
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associated with lower HF risk among patients with CKD, but not among patients without
CKD. We show that integrating CKD phenotype information, survival analyses and network
analysis can highlight clinically relevant defects in specific biological pathways and might
focus further investigations on developing therapeutic targets in patients with CKD. Validation
in additional cohorts with adequate numbers of patients with CKD is needed to confirm asso-
ciations of novel proteins with HF.
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